Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1988;95(3):413-7.
doi: 10.1007/BF00181958.

The alpha 2-adrenoceptor antagonists idazoxan and yohimbine increase rates of DRL responding in rats

Affiliations

The alpha 2-adrenoceptor antagonists idazoxan and yohimbine increase rates of DRL responding in rats

D J Sanger. Psychopharmacology (Berl). 1988.

Abstract

Previous studies have reported that antidepressant drugs exert specific effects on responding maintained by DRL schedules of reinforcement, giving rise to increased frequencies of reinforcement. In order to investigate whether the alpha 2-adrenoceptor antagonist idazoxan would produce similar effects, the actions of this compound were compared with those of yohimbine, imipramine, mianserin and d-amphetamine in rats trained to lever press for food reinforcement on a DRL 60-s schedule. Neither imipramine nor mianserin produced any effects on response rate or reinforcement frequency, except at the highest doses. In contrast, both idazoxan and yohimbine gave rise to dose-related increases in rates of responding and consequent decreases in reinforcement frequencies. Amphetamine also increased responding, but higher doses of this drug produced marked hyperactivity and stereotyped movements which were not observed after idazoxan and yohimbine. Although the present behavioural baseline was not sensitive to antidepressants, it demonstrated an unexpected activity of two alpha 2-adrenoceptor antagonists which deserves further investigation.

PubMed Disclaimer

References

    1. Life Sci. 1987 Aug 31;41(9):1083-8 - PubMed
    1. Nature. 1978 Oct 12;275(5680):479-80 - PubMed
    1. Br J Pharmacol. 1987 Apr;90(4):675-85 - PubMed
    1. J Pharmacol Exp Ther. 1980 Sep;214(3):635-41 - PubMed
    1. Br J Pharmacol. 1983 Mar;78(3):489-505 - PubMed

LinkOut - more resources